Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live

The product has been deemed bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (NDA - 019443). Glenmark plans to begin distribution in November 2025, further strengthening its injectables portfolio in the US market. According to IQVIA sales data for the 12-month period ending August 2025, the market for 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) achieved annual sales of approximately $63.8 million. Commenting on the launch, Marc Kikuchi, president & business head, North America said, 'We are pleased to announce the expansion of our injectable portfolio to include the upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial, which further reinforces our dedication to bring quality and affordable alternatives to market to patients in need.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredient to regulated and semi-regulated markets. The company's consolidated net profit tanked 23.4% to Rs 260.79 crore on 5.1% decline in revenue from operations to Rs 3059.33 crore in Q1 FY26 over Q1 FY25. Shares of Glenmark Pharmaceuticals fell 1.50% to Rs 1,869.60 on the BSE. Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial. Glenmark's 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (Abbott) NDA - 019443. Glenmark will begin distribution in November 2025. According to IQVIA' sales data for the 12-month period ending August 2025, the 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) market achieved annual sales of approximately $63.8 million. Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1891.5, up 0.02% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.04% on the day, quoting at 25733.2. The Sensex is at 83888.29, down 0.06%. Glenmark Pharmaceuticals Ltd has slipped around 4.04% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has slipped around 2.63% in last one month and is currently quoting at 22175.4, up 0.8% on the day. The volume in the stock stood at 3.83 lakh shares today, compared to the daily average of 5.8 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1898.4, down 0.25% on the day. Glenmark Pharmaceuticals Ltd is up 11.31% in last one year as compared to a 7.24% jump in NIFTY and a 1.26% jump in the Nifty Pharma index.The PE of the stock is 28.47 based on TTM earnings ending June 25.Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1870.8, up 1.49% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.51% on the day, quoting at 25920.5. The Sensex is at 84560.96, down 0.51%. Glenmark Pharmaceuticals Ltd has slipped around 4.51% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has slipped around 2.59% in last one month and is currently quoting at 22430.7, down 0.6% on the day. The volume in the stock stood at 5.13 lakh shares today, compared to the daily average of 5.64 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1878.9, up 1.34% on the day. Glenmark Pharmaceuticals Ltd is up 10.4% in last one year as compared to a 7.09% jump in NIFTY and a 1.93% jump in the Nifty Pharma index.The PE of the stock is 27.76 based on TTM earnings ending June 25.Powered by Capital Market - Live

The company confirmed that its product is bioequivalent and therapeutically equivalent to the reference drug, Naropin Injection, marketed by Fresenius Kabi USA, LLC (NDA ' 020533). Glenmark plans to commence distribution of the injection from November 2025. According to IQVIA sales data for the 12-month period ending August 2025, the Naropin Injection market recorded annual sales of approximately $20.9 million in the US. Commenting on the launch, Marc Kikuchi, president & business head, North America said, 'We are pleased to announce the launch of Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. This launch represents another important addition to Glenmark's expanding injectable portfolio and reinforces our dedication to bring quality and affordable alternatives to market for patients in need.' Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company's consolidated net profit jumped 49.9% to Rs 215.48 crore on 7.4% rise in revenue from operations to Rs 1505.62 crore in Q1 FY26 over Q1 FY25. The scrip rose 0.05% to Rs 1,856.60 on the BSE. Powered by Capital Market - Live

Glenmark Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 26 September 2025, inter alia, have recommended the interim dividend of Rs 2.5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark), today announced that it has entered into an exclusive license and collaboration agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC). Under the terms of the agreement, Glenmark obtains exclusive rights to develop and commercialize Trastuzumab Rezetecan (SHR-A1811) worldwide, excluding Mainland China, the Hong Kong SAR, the Macao SAR, Taiwan Region, USA, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan and Uzbekistan. Glenmark will pay an upfront payment of US$18 million. Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion. Based on the net sales of Trastuzumab Rezetecan within the licensed territory, Glenmark will pay corresponding royalties to Hengrui.  Powered by Capital Market - Live

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 26 September 2025.Powered by Capital Market - Live

Glenmark Pharmaceuticals has fixed 30 September 2025 as record date for payment of interim dividend, if declared. Powered by Capital Market - Live